indiamed
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
facebook x icon x icon linkedin linkedin
new-product

World’s First Generic Eribulin for Treatment of Metastatic Breast Cancer Launched in India

IMT News Desk
Emcure Pharmaceuticals, a leading integrated global pharmaceutical company from India, today, announced the launch of the world’s first generic version of Eisai Pharmaceutical’s Halaven (Eribulin) for the treatment of metastatic breast cancer (MBC). Emcure will be marketing the drug under brand name ‘Eribilin’, with an aim to offer high-quality and cost-effective treatment option to breast cancer patients in India.  As per reports from the Indian Council of Medical Research & Population Based Cancer Registry (ICMR-PBCR) Breast cancer is the commonest occurring cancer in urban Indian women and the second commonest in rural women. Although world class breast cancer treatment is available in India, majority of the patients are unable to access it due to lack of quality infrastructure, skills and above all financial resources. “Incidence of breast cancer is on the rise in India and being a price sensitive market with low awareness, with the launch of Eribilin we aim to provide a proven and cost-effective treatment of high quality and efficacy as offered by the innovator brand. It is a proud moment for Emcure to launch Eribilin, the world’s first generic version of the innovator brand that will break the price barrier making it a cost-effective option for patients,” said Sainath Iyer, President – Business Strategy & Specialty Business – Emcure Pharmaceuticals Ltd. Emcure’s Eribilin has been approved by DCGI to be marketed in India. “Breast cancer is the most common type of cancer affecting women in India and its incidence is on the rise. Currently available treatment for triple negative breast cancer in India is out of reach of most patients due to its high cost. Emcure’s Eribilin will change this scenario by offering a world-class, high quality drug at a reasonable price to the patients in India” said Sainath Iyer, President – Business Strategy & Specialty Business – Emcure Pharmaceuticals Ltd. Eribulin is a non-taxane inhibitor of microtubule dynamics and remains effective in MBC previously treated with an anthracycline and a taxane. Eribulin is a complex API derived from a marine natural product called Halocondrin B. “Emcure’s R&D resources are equipped with technical competence and state-of-the-art development facility to develop such complex generics. Generic Eribulin is a landmark achievement of Emcure’s R&D efforts both in API manufacturing and formulation,” said Dr. Mukund Gurjar, Chief Scientific Officer, Emcure Pharmaceuticals. Emcure will manufacture generic Eribulin at its state of the art plant at Hinjewadi in Pune and market it at a cost which will be approximately 40% less than the innovator brand bringing hope to millions of breast cancer patients in India. The drug would currently be marketed in India, however Emcure plans to register the brand in international markets as well, wherever the drug is about to go off-patent.

Recommended

Alcon launches PRECISION1 contact lens

Herbalife India launches Sleep Enhance

AbbVie introduces Venetoclax in India, targeting blood cancer treatment gaps

Dräger introduces anaesthesia workstations Atlan A100

Sun Pharma introduces novel drug Fexuclue to treat erosive esophagitis

Cadila Pharma unveils migraine relief reformulated Vasograin EC

Alcon Introduces Personalised LASIK Treatment

Cadila Pharma launches Cadilose

Indiamedtoday

A premier media platform empowering healthcare professionals with critical business insights, news, and innovations to excel in a rapidly evolving industry.

EMAIL editorial@indiamedtoday.com

EMAIL sales@indiamedtoday.com

quick links

news health it interview opinion strategy magazine privacy policy terms and conditions

subscribe to our newsletter

Stay updated with the latest breakthroughs in Indian healthcare, medical research, and wellness insights.

    follow us

    facebook x icon x icon linkedin linkedin
    Copyright © 2025 INDIAMED TODAY Marketed By Screetract Solutions